The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).
 
Jeffrey Graham
Honoraria - Ipsen; Janssen Oncology; Pfizer
 
Naveen S. Basappa
Honoraria - Astellas Pharma; Eisai; Ipsen; Janssen; Merck; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Ipsen; Janssen; Merck; Pfizer; Roche Canada
 
Sunita Ghosh
No Relationships to Disclose
 
Hanbo Zhang
Honoraria - Merck
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)
 
Aly-Khan A. Lalani
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; Tersera
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Roche/Genentech; Tersera
Research Funding - BioCanRx (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Roche (Inst)
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Denis Soulieres
Honoraria - Adlai Nortye; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Novartis; Pfizer
Consulting or Advisory Role - Adlai Nortye; Ipsen; Merck; Pfizer
Research Funding - Adlai Nortye (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Vincent Castonguay
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen; Novartis
 
Christian K. Kollmannsberger
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Merck KGaA; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Janssen; Merck; Merck KGaA; Pfizer
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
Michel Pavic
Honoraria - Amgen; Astellas Pharma; BMS; Janssen; Lilly; Novartis; Pfizer
Travel, Accommodations, Expenses - Janssen
 
Lori Wood
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Anil Kapoor
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst)
 
Georg A. Bjarnason
Stock and Other Ownership Interests - Merck
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; Merck; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Research Funding - Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer